DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Kapur A, O’Connor-Semmes R, Hussey EK et al.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC.
BMC Pharmacol Toxicol 2013;
14: 26
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.